

| | | | |
|--|--|--|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 16952CON1CIP3 | Application No. 10/726,904 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant Kei Aoki | |
| | | Filing Date December 2, 2003 | Group Art Unit 1654 |

U.S. Patent Documents

| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate |
|------------------|-----------|-----------------|------------------|----------------|-------|----------|----------------------------|
| | 1. | 4,234,566 | 11/18/80 | Packman et al. | | | |
| | 2. | 4,713,240 | 12/15/87 | Wilkins et al. | | | |
| | 3. | 4,720,494 | 01/19/88 | Felger et al. | | | |
| | 4. | 4,832,936 | 05/23/89 | Holter et al. | | | |
| | 5. | 4,935,969 | 06/26/90 | Farnsworth | | | |
| | 6. | 5,512,547 | 04/01/1996 | Johnson et al. | | | |
| | 7. | 5,714,468 | 02/01/98 | Binder et al. | | | |
| | 8. | 6,306,403 | 10/23/01 | Donovan | | | |
| | 9. | 6,319,505 | 11/20/01 | Aoki et al. | | | |
| | 10. | 6,333,037 | 12/25/01 | Aoki et al. | | | |
| | 11. | 6,372,226 | 04/16/02 | Aoki et al. | | | |
| | 12. | 6,395,277 | 05/28/02 | Graham | | | |
| | 13. | 6,372,226 | 04/16/02 | Aoki et al. | | | |
| | 14. | 6,448,231 | 09/10/02 | Graham | | | |
| | 15. | 6,458,365 | 10/01/02 | Aoki et al. | | | |
| | 16. | 6,500,436 | 12/31/02 | Donovan | | | |
| | 17. | 6,623,742 | 09/23/03 | Voet | | | |
| | 18. | 6,683,049 | 01/27/04 | Aoki et al. | | | |
| | 19. | 6,872,397 | 03/29/05 | Aoki et al. | | | |
| | 20. | 6,887,476 | 05/03/05 | Aoki et al. | | | |
| | 21. | 6,939,852 | 09/01/05 | Graham | | | |
| | 22. | 6,974,578 | 12/13/05 | Aoki et al. | | | |
| | 23. | 6,986,893 | 01/17/06 | Aoki et al. | | | |
| | 24. | 2003/0118598 | 06/26/03 | Hunt | | | |
| | 25. | 2004/0126397 | 07/01/04 | Aoki et al. | | | |

Foreign Patent Documents or Published Foreign Patent Applications

| Examiner | Desig. | Document | Publication | Country or | Class | Subclass | Translation |
|----------|--------|----------|-------------|------------|-------|----------|-------------|
|----------|--------|----------|-------------|------------|-------|----------|-------------|

| | |
|-------------------------------------|-------------------------------|
| Examiner Signature /Anish Gupta/ | Date Considered 02/19/2008 |
|-------------------------------------|-------------------------------|

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AG/

| | | | |
|--|--|--|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 16952CON1CIP3 | Application No. 10/726,904 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant Kei Aoki | |
| | | Filing Date December 2, 2003 | Group Art Unit 1654 |

| | | | | | | | Yes | No |
|--|-----|-------------|----------|----|--|--|-----|----|
| | 26. | WO94/000081 | 01/06/94 | WO | | | | |
| | 27. | WO94/015629 | 07/21/94 | WO | | | | |
| | 28. | WO95/017904 | 07/06/95 | WO | | | | |
| | 29. | 2272697 | 05/25/94 | GB | | | | |
| | 30. | 19852981 | 05/28/00 | DE | | | | |

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|---|-----------|--|
| Examiner Initial | Desig. ID | Document |
| | 31. | Anderson et al., "Botulinum Toxin Treatment of Spasmodic Torticollis," <u>J. of the Royal Soc. Of Med.</u> , 1992, 85:524-529 |
| | 32. | "Athena files US and Canadian Investigational New Drugs," <u>Scrip</u> , June 5, 1992, No. 1724, p. 29 |
| | 33. | "Athena Outlines Business Strategy," <u>Marketletter</u> , Oct. 5, 1992 |
| | 34. | Blasl et al., "Botulinum Neurotoxin A Selectively Cleaves the Synaptic Protein SNAP-25," <u>Nature</u> , 1993, 365:160-163 |
| | 35. | Berardelli et al., "Botulinum Toxin Treatment in Patients with Focal Dystonia and Hemifacial Spasm. A multicenter study of the Italian Movement Disorder Group," <u>Neurol. Sci.</u> , 1993, 14:361-367 |
| | 36. | Bergmann et al., "Selective Degeneration of Sudomotor Fibers in Ross Syndrome and Successful Treatment of Compensatory Hyperhidrosis with Botulinum Toxin," <u>Muscle & Nerve</u> , 1998, 21(12):1790-1793 |
| | 37. | Biglan, "Experience with Botulinum A toxin (Oculinum) in the treatment of strabismus," <u>Contemp. Opth. Forum</u> , 1987, 5(6): 230-240 |
| | 38. | Blitzer et al., "Electromyographic Findings in Focal Laryngeal Dystonia (Spastic Dysphonia)," <u>Ann. Otol. Rhino. Laryngol.</u> , 1985, 94:591-594 |
| | 39. | Bodde et al., "Transdermal Peptide Delivery," <u>Biochem. Soc. Trans.</u> , 1989, 17(5): 943-945 |
| | 40. | "BOTOX," 2000, 9 pages [web site] |
| | 41. | "Botulinum Toxin for the Treatment of Facial Lines and Wrinkles," 2005, [www.shorelaser.com/BotoxA.html], pp. 1-7 |
| | 42. | "Botulinum-Toxin hilft bei Augenleiden," (December 1986) |
| | 43. | "Botulinum Toxin may be useful in a range of muscular disorders," <u>Int. Med. News</u> , 1991, 15:24(16):36 |
| | 44. | Borodic et al., "Botulinum B Toxin as an Alternative to Botulinum A Toxin: A Histologic Study," <u>Ophthalm. Plast. Reconstr. Surg.</u> , 1993, 9(3):182-190 |
| | 45. | Borodic et al., "Clinical and scientific aspects of botulinum A toxin," <u>Ophthalm Clinics of N. America</u> , 1991, 4(3):491-503 |
| | 46. | Boroff et al., "Amino acid analysis of the isolated and purified components from crystalline toxin of Clostridium botulinum type A," <u>Infect. Immun.</u> , 1970, 2(5):679-680 |
| | 47. | Brin et al., "Assessment: The clinical usefulness of Botulinum toxin A in treating neurologic disorders," <u>Neurology</u> , 1990, 40: 1332-1336 |

| | |
|--|-------------------------------|
| Examiner Signature /Anish Gupta/ | Date Considered 02/19/2008 |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | |
|--|--|--|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 16952CON1CIP3 | Application No. 10/726,904 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant Kei Aoki | |
| | | Filing Date December 2, 2003 | Group Art Unit 1654 |

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|---|-----------|---|
| Examiner Initial | Desig. ID | Document |
| | 48. | Brin et al., "Localized Injections of Botulinum Toxin for the Treatment of Focal Dystonia and Hemifacial Spasm," <u>Advances in Neurology</u> , 1988, 50:599-608 |
| | 49. | Buckelew, "Fibromyalgia: a rehabilitation approach. A review.," <u>Am. J of Phy. Med. & Rehab.</u> , 1989, 68(1):37-42 |
| | 50. | Callaway, "Botulinum Toxin Type B: Pharmacology and Biochemistry," <u>Clinics in Dermatology</u> , 2004, 22:23-29 |
| | 51. | "Cervical Dystonia" [www.fpnotebook.com/NEU151.htm]; pp. 1-2 (retrieved 09-03-2003) |
| | 52. | Choi et al., "Transdermal delivery of bioactive peptides: the effect of n-decylmethyl sulfoxide, pH, and inhibitors on Enkephalin metabolism and transport," <u>Pharm. Res.</u> , 1990, 7(11): 1099-1106 |
| | 53. | Cioffi et al., "Microvasculature of the Anterior Optic Nerve," <u>Surv. Of Ophthal.</u> , 1994, 38: S107-S116 |
| | 54. | Cohen et al., "Treatment of Focal Dystonias of the Hand with Botulinum Toxin Injection" <u>Neurology</u> , 1987, 37:123-124 |
| | 55. | Clark, "Cervical Dystonia Following Exposure to High-G Forces," <u>Aviat. Space Environ. Me.</u> , 1990, 61: 935-937 |
| | 56. | Cosgrove et al., "Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse model," <u>Dev. Med. And Child Neurol.</u> , 1994, 36: 379-385 |
| | 57. | Cosgrove et al., "Botulinum toxin in the management of lower limb in cerebral palsy," <u>Dev. Med. And Child Neurol.</u> , 1994, 36: 386-396 |
| | 58. | Dasgupta et al., "Purification of Clostridium botulinum type A toxin, Biochimica," <u>Biochim. Biophys. Acta.</u> , 1970, 214(2):343-349 |
| | 59. | Dasgupta et al., "Role of a protease in natural activation of Clostridium botulinum neurotoxin," <u>Infect. Immun.</u> , 1972, 6(4):587-590 |
| | 60. | Dasgupta et al., "Separation of toxin and Hemagglutinin from crystalline toxin of Clostridium botulinum type A by anion exchange chromatography and determination of their dimensions by gel filtration," <u>J. Biol. Chem.</u> , 1969, 243(5):1065-1072 |
| | 61. | Dasgupta, "The Structure of Botulinum Neurotoxin," <u>Botulinum Neurotoxin and Tetanus Toxin</u> , 1989, pp. 53-67 |
| | 62. | Davis et al., "Significant Improvement of Stiff-Person Syndrome After Paraspinal Injection of Botulinum Toxin A," <u>Movement Disorders</u> , 1993, 8(3):371-373 |
| | 63. | Departments, Programs and Services [www.gillettechildren.org/about-us/staff/departments.html] |
| | 64. | Duane, "Spasmodic Torticollis," <u>Adv. Neuro.</u> , 1988, 49: 135-150 |
| | 65. | Dunn et al., <u>Ophthal.</u> , 1986, 93(4): 470-475 |
| | 66. | Eames et al., "The effect of Botulinum toxin A on gastrocnemius length: magnitude and duration of response," <u>Dev. Med and Child Neurol.</u> , 1999, 41: 226-232 |
| | 67. | "Elan Pharmaceuticals exploring potential use of MYOBLOC (Botulinum Toxin Type B) in Spasticity, Pain and Cermatiolic Applications," [www.biospace.com/news_story.cfm?StoryID=4964504&full=1] |
| | 68. | Elston et al., "Paralytic Strabismus: The Role of Botulinum Toxin," <u>Br. J. Ophthalmol.</u> , 1985, 69(12):891-896. |
| | 69. | Elston, "Thyroid Eye Disease," <u>Eye</u> , 1990, 4(pt. 4):vii |

| | |
|--|-------------------------------|
| Examiner Signature /Anish Gupta/ | Date Considered 02/19/2008 |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AG/

| | | | |
|--|--|--|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 16952CON1CIP3 | Application No. 10/726,904 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant Kei Aoki | |
| | | Filing Date December 2, 2003 | Group Art Unit 1654 |

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|---|-----------|--|
| Examiner Initial | Desig. ID | Document |
| | 70. | "Enzyme Linked Immuno Sorbent Assays (ELISAS) to Detect Botulinum Toxins Using high Titer-Rabbit Anti-Sera," <u>Botulinum and Tetanus Neurotoxins</u> , 1993, Plenum Press |
| | 71. | Escobar et al., "Myofascial Pain Syndrome," <u>Orth. Review</u> , 1987, 16(10):708-713 |
| | 72. | Eustis et al., "Botulinum Toxin," <u>Ophthalm. Clinics of N. Am.</u> , 1989, 2(1): 163-172 |
| | 73. | Gammon et al., "Botulinum chemodenervation treatment of strabismus," <u>J. Ped. Ophthalm. S.</u> , 1989, 96(7): 931-934 |
| | 74. | Gjerstad et al., "Treatment of Focal Dystonia with Botulinum Toxin," <u>Tidsskrift for Den Norske Laegeforening</u> , 1991, 111(21):2637-2639 |
| | 75. | Glogau, "Botulinum A Neurotoxin for Axillary Hyperhidrosis," <u>Dermatol. Surg.</u> , 1998, 24(8):817-819 |
| | 76. | Goodnough et al., "Stabilization of Botulinum Toxin Type A During Lyophilization," <u>Applied and Environmental Microbiology</u> , 1992, 58(10):3426-3428 |
| | 77. | Greene et al., "Use of Botulinum Toxin Type F Injection to Treat Torticollis in Patients with Immunity of Botulinum Toxin Type A," <u>Movement Disorders</u> , 1994, 8(4): 479-483 |
| | 78. | Grusser, "Die ersten systematischen Beschreibungen und tierexperimentellen Untersuchungen des Botulismus," <u>Sudhoffa Archi.</u> , 1986, 70(2): 167-186 |
| | 79. | Henesen, "Deadly toxin calms excited muscles," <u>New Scientist</u> , 1990, New Science Publications, London, GB, No. 1746, p. 24 |
| | 80. | Humphry, "Botulinum Toxin: A New Ally of an old adversary," <u>BMJ</u> , 1989, 298:136-137 |
| | 81. | Jankovic et al., "Botulinum A toxin for cranial-cervical dystonia: A double-blind, placebo-controlled study," <u>Neurology</u> , 1987, 37:616-623 |
| | 82. | Jankovic et al., "Therapy with Botulinum Toxin," 1994, Marcel Dekker, Inc., p. 76 |
| | 83. | Jedynak et al., "Treatment of spasmodic torticollis by local injections of Botulinum toxin," <u>Rev. Neurol.</u> , 1990, 146:440-443 |
| | 84. | Jost et al., "Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX(R)) in healthy volunteers," <u>J. Neurol. Transm.</u> , 2005, 112: 905-913 |
| | 85. | Kaszynski et al., "Mouse Foot Screen for the Inhibition of Sweating by Anticholinergic Drugs," <u>The J. of Investi. Derma</u> , 1974, 62:510-513 |
| | 86. | Kerner, "Das Fettgift oder die fettsaure und ihre wirkungen auf den thierischen organismus, ein beytrag zur untersuchung des in verdorbenen wrusten giftig wirkenden stoffes," <u>Stuttgart und Tubingen: Cotta</u> , 386 pages |
| | 87. | Knight, "Botulinum Toxin Types A, B and D Inhibit Catecholamine Secretion from Bovine Adrenal Medullary Cells," <u>FEBS. Lett.</u> , 1986, 207(2): 222-226 |
| | 88. | Kondo et al., "Modification of the action of pentagastrin on acid secretion by Botulinum toxin" <u>Experientia</u> , 1977, 33(6):750-751 |
| | 89. | Lewis, "Wrinkles in Motion the Ultimate Guide," 2002 [website] |
| | 90. | Liedtke et al., "Transdermal administration of insulin in type II diabetes, Results of a clinical pilot study," <u>Arzneimittelforschung</u> , 1990, 40(8): 884-886 |
| | 91. | Magoon, <u>Ophthalm.</u> , 1989, 96(7): 931-934 |
| | 92. | Magoon, "Botulinum Toxin chemo-denervation for strabismus in infants and children," <u>J. Ped. Ophthalm. S.</u> , 1984, 21(3): 110-113 |
| | 93. | Melling et al., <u>Eye</u> , 1988, 2:16-23 |

| | |
|--|-------------------------------|
| Examiner Signature /Anish Gupta/ | Date Considered 02/19/2008 |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AG/

| | | | |
|--|--|--|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 16952CON1CIP3 | Application No. 10/726,904 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant Kei Aoki | |
| | | Filing Date December 2, 2003 | Group Art Unit 1654 |

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|---|-----------|---|
| Examiner Initial | Desig. ID | Document |
| | 94. | Mezaki et al., "Combined use of Type A and F Botulinum Toxins for Blepharospasm: A Double-Blind Control Trial," <u>Movement Disorders</u> , 1999, 14(6):1017-1020 |
| | 95. | Naumann et al., "Botulinum Toxin for Focal Hyperhidrosis: Technical Considerations and Improvements in Application," <u>Brit. J. of Derm.</u> , 1998, 139:1123-1124 |
| | 96. | Naumann et al., "Botulinum Toxin for Palmar Hyperhidrosis," <u>Lancet</u> , 1997, 349(9047):252 |
| | 97. | Naumann et al., "Focal Hyperhidrosis," <u>Arch. Dermatol.</u> , 1998, 134:301-304 |
| | 98. | Naver et al., "The Treatment of Focal Hyperhidrosis with Botulinum Toxin," <u>The Eur. J. of Neur.</u> , 1997, 4(2):S75-S79 |
| | 99. | News Publication: "Marketing Approvals," <u>Med. World News</u> , 1990, 31(5): 2 |
| | 100. | News Publication: "Porton launches Dysport in UK," <u>Scrip</u> , 1991, 1607: 23 |
| | 101. | News Publication: "U.S. Food & Drug Administration approves coulinum for strabismus in patients 12 years of age and above and for blepharospasm," <u>Bin. Vis. Quart</u> , 1990, 5(2): 61 |
| | 102. | Odderson, "Axillary Hyperhidrosis: Treatment with Botulinum Toxin A," <u>Arch. Phys. Med. Rehab.</u> , 1998, 79:350-352 |
| | 103. | Overmyer, "Botulinum Toxin: Poison with a purpose" <u>Mod. Med.</u> , 1991, 59: 112-116 |
| | 104. | Park et al., "Binding of Clostridium Botulinum type B toxin to rat brain synaptosome," <u>Fems. Micro. Lett.</u> , 1990, 60(3): 243-247 |
| | 105. | Pope, "Approval Unwrinkles Elan's Brow," [http://www.ideaadvisor.com/company/article.asp?aid=7368] |
| | 106. | Poewe et al., "Experience with Botulinum Toxin in Cervical Dystonia; Therapy with Botulinum Toxin," 1994, pp. 267-278 |
| | 107. | Rader, "Biopharmaceutical Products in the U.S. Market," <u>Biopharma</u> , 2001, 332:271-274 |
| | 108. | Reichl et al., "Hyperesthesia Associated with Hyperextension Injuries of the Neck," <u>Injury</u> , 18(4): 234 |
| | 109. | Roggenkamper et al., "Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm," <u>J. Neurol. Transm.</u> , 2006, 113: 303-312 |
| | 110. | Rosenbaum et al., "Vertical rectus muscle transposition and Botulinum Toxin (Oculinum) to medical rectus for abducens palsy," <u>Arch. Ophthal.</u> , 1989, 107(6): 820-823 |
| | 111. | Sanchez et al., "Propiedades Farmacologicas y Usos Terapeuticos de la Toxina Botulinica," <u>Farmacia Clinica</u> , 1992, 9(5):404-413 |
| | 112. | Sanders et al., "Drug delivery systems and routes of administration of peptide and protein drugs," <u>Eur. J. of Drug. Met. And Pharma</u> , 1990, 12(2): 95-102 |
| | 113. | Sasaki et al., "Effect of pyrrolidone derivatives on lipid membrane and protein conformation as transdermal penetration enhancer," <u>J. Pharmacobio-Dyn.</u> , 1990, 13: 468-474 |
| | 114. | Sato et al., "Purification and some properties of a proteinase and an esterase released from Clostridium Botulinum A, B, and F types," <u>Nippon Saik. Zasshi</u> , 1973, 28(4): 367-374 |
| | 115. | Savino et al., "Hemifacial Spasm treated with Botulinum A toxin injection," <u>Arch. Ophthalmol.</u> , 1985, 103(9):1305-1306 |
| | 116. | Schantz, "Use of crystalline type A botulinum toxin in medical research," <u>Biomedical aspects of botulism</u> , 1981, Academic Press, New York, pp. 143-150 |
| | 117. | Schiavo et al., "Botulinum Neurotoxins are Zinc Proteins," <u>J. Biol. Chem.</u> , 1992, 267(33):23479-23483 |

| | |
|--|-------------------------------|
| Examiner Signature /Anish Gupta/ | Date Considered 02/19/2008 |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AG/

| | | | |
|--|--|--|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 16952CON1CIP3 | Application No. 10/726,904 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant Kei Aoki | |
| | | Filing Date December 2, 2003 | Group Art Unit 1654 |

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|---|-----------|--|
| Examiner Initial | Desig. ID | Document |
| | 118. | Schnider et al., "Double-Blind Trial of Botulinum A Toxin for the Treatment of Focal Hyperhidrosis of the Palms," <u>Brit. J. of Derma.</u> , 1997, 136(4):548-552 |
| | 119. | Schwartz, "Circulatory Defects of the Optic Disk and Retina in Ocular Hypertension and High Pressure Open Angle Glaucoma," <u>Survey of Ophthal.</u> , 1994, 38 |
| | 120. | Scott, "Botulinum Toxin Treatment of Strabismus and Blepharospasm, a multiple investigator study," <u>Proceedings of the 5th meeting of the internat'l strabismological association</u> , 1986, 483-485 |
| | 121. | Scott, "Vol VII Module 12: Botulinum Toxin treatment of strabismus," <u>Am. Aca. Ophthal.</u> , 1989, 2:1-11 |
| | 122. | Scott et al., <u>Ophthal.</u> , 1985, 92(5): 676-683 |
| | 123. | Scott et al., "Botulinum treatment of strabismus in children," <u>Trans. Am. Ophthal. Soc.</u> , 1990, 87: 174-180, 180-184 |
| | 124. | Shelley et al., "Botulinum Toxin Therapy for Palmar Hyperhidrosis," <u>J. of Am. Acad. Of Derma.</u> , 1998, 32:227-229 |
| | 125. | Simpson, "Current Concepts of the Mechanism of Action of Clostridial Neurotoxins," <u>Botulinum and Tetanus Neurotoxins</u> , 1993, Plenum Press, New York, pp. 1-15 |
| | 126. | Simpson, "The Origin Structure and Pharmacological Activity of Botulinum Toxin," <u>Pharmacol. Reviews</u> , 1981, 33(3):155-188 |
| | 127. | Simpson, "Clinically Relevant Aspects of the Mechanism of Action of Botulinum Neurotoxin," <u>Journal of Voice</u> , 1992, 6(4):358-364 |
| | 128. | Simons, "Fibrositis/fibromyalgia: a form of myofascial trigger points?," <u>Am. J. of Med.</u> , 1986, 81(3A):93-98 |
| | 129. | Snow et al., "Treatment of Spasticity with Botulinum Toxin: A Double-Blind Study" <u>Annals of Neurology</u> , 1990, 28(4):512-515 |
| | 130. | Southern Utah Spine & Rehabilitation Special Treatment and Tests [http://physical-medicine.net/special.htm] |
| | 131. | Srinivisan et al., "Iontophoresis of polypeptides: effect of ethanol pretreatment of human skin," <u>J. Pharma. Sci.</u> , 1990, 79(7) |
| | 132. | Stacy et al., "Efficacy of Botulinum toxin type B for treatment of blepharospasm: Report of two cases," <u>Naunyn-Schmiedeberg's Archives of Pharmacology</u> , 2002, 365(2):R44 |
| | 133. | Stevens et al., "Development and Properties of the secretory response in rat sweat glands: Relationship to the induction of cholinergic function in sweat gland innervation," <u>Dev. Bio.</u> , 1987, 123:179-190 |
| | 134. | Tonneson et al., "A double blind trial of a 16-hour transdermal nicotine patch in smoking cessation," <u>New Eng. J. Med.</u> , 1991, 325(5): 311-315 |
| | 135. | Tsui et al., "Botulinum Toxin Type B in the Treatment of Cervical Dystonia: A Pilot Study," <u>Neurology</u> , 1995, 45(11):2109-2110 |
| | 136. | Verhoef et al., "Transport of peptide and protein drugs across biological membranes," <u>Eur. J. Drug Metab.</u> , 1990, 15(2): 83-93 |
| | 137. | Wagman et al., "Botulinum Type A toxin: properties of a toxic dissociation product," <u>Arch. Biochem. Biophys.</u> , 1953, 45:375-383 |
| | 138. | Wright et al., "The Spastic Mouse and the search for an animal model of spasticity in human beings," <u>Clin. Orth. And Related Res.</u> , 1990, 253: 12-19 |

| | |
|--|-------------------------------|
| Examiner Signature /Anish Gupta/ | Date Considered 02/19/2008 |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AG/

| | | | |
|--|--|--|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 16952CON1CIP3 | Application No. 10/726,904 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant Kei Aoki | |
| | | Filing Date December 2, 2003 | Group Art Unit 1654 |

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|---|-----------|--|
| Examiner Initial | Desig. ID | Document |
| | 139. | Yakovleff et al., "Indications and use of botulinic toxin in the treatment of spasticity," <u>Annales de Re. et de Med. Phy.</u> , 1994, 36(5):359-363 |
| | 140. | "The Merck Manual of Diagnosis and Therapy," 1987, pp. 1420-1421, 1449-1551 |
| | 141. | National Institutes of Health, "Clinical Use of Botulinum Toxin, Consensus Development Conference Statement," Nov. 12-14, 1990, http://consensus.nih.gov/1990/1990BotulinumToxin083html.htm , pp. 1-18 |

| | |
|--|-----------------------------------|
| Examiner Signature /Anish Gupta/ | Date Considered 02/19/2008 |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AG/